Page last updated: 2024-11-13
gliovirin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gliovirin: from Gliocladium virens; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 101288424 |
| MeSH ID | M0111558 |
Synonyms (11)
| Synonym |
|---|
| gliovirin |
| 6t311l5925 , |
| 12h-8,11a-(iminomethano)-1ah,7h-(1,2,4)dithiazepino(4,3-b)oxireno(e)(1,2)benzoxazine-7,13-dione, 4,4a,8,9-tetrahydro-4-hydroxy-9-(2-hydroxy-3,4-dimethoxyphenyl)-, (1as-(1aalpha,4beta,4abeta,8alpha,9beta,11aalpha,12as*))- |
| unii-6t311l5925 |
| 12h-8,11-(iminomethano)-1ah,7h-(1,2,4)dithiazepino(4,3-b)oxireno(e)(1,2)benzoxazine-7,13-dione, 4,4a,8,9-tetrahydro-4-hydroxy-9-(2-hydroxy-3,4-dimethoxyphenyl)-, (1as-(1aalpha,4beta,4abeta,8alpha,9beta,11aalpha,12ar*))- |
| (1as-(1aalpha,4beta,4abeta,8alpha,9beta,11aalpha,12ar*))-4,4a,8,9-tetrahydro-4-hydroxy-9-(2-hydroxy-3,4-dimethoxyphenyl)-12h-8,11-(iminomethano)-1ah,7h-(1,2,4)dithiazepino(4,3-b)oxireno(e)(1,2)benzoxa |
| mfcd08274579 |
| 12h-8,11a-(iminomethano)-1ah,7h-(1,2,4)dithiazepino(4,3-b)oxireno(e)(1,2)benzoxazine-7,13-dione, 4,4a,8,9-tetrahydro-4-hydroxy-9-(2-hydroxy-3,4-dimethoxyphenyl)-, (1as,4r,4as,8s,9r,11ar,12as)- |
| 12h-8,11a-(iminomethano)-1ah,7h-(1,2,4)dithiazepino(4,3-b)oxireno(e)(1,2)benzoxazine-7,13-dione, 4,4a,8,9-tetrahydro-4-hydroxy-9-(2-hydroxy-3,4-dimethoxyphenyl)-, (1as-(1a.alpha.,4.beta.,4a.beta.,8.alpha.,9.beta.,11a.alpha.,12ar*))- |
| Q27265473 |
| (1r,3s,5s,8r,9s,13s,14r)-8-hydroxy-14-(2-hydroxy-3,4-dimethoxyphenyl)-4,10-dioxa-15,16-dithia-11,18-diazapentacyclo[11.3.2.01,11.03,5.03,9]octadec-6-ene-12,17-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.79) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||